Company Monitoring Page for Incyte

latest headlines for company on cafepharma

Risk-Reward Balanced at Incyte
Yahoo/Zacks.com
Wed, 06/15/11 - 09:26 pm
Tags:
Incyte, Eli Lilly, Novartis
Incyte Reports Additional Analyses of Symptomatic Improvement and Quality of Life with Ruxolitinib (INC424) in Patients with Myelofibrosis from the COMFORT-I Study
BusinessWire
Sun, 06/12/11 - 10:36 am
Tags:
Incyte, ruxolitinib, myelofibrosis
A Dull ASCO And The Usual Sell-Off
Investopedia
Tue, 06/7/11 - 07:34 pm
Tags:
ASCO, Celgene, Bristol-Myers Squibb, Incyte, Exelixis, Novartis, YM BioSciences, Neoprobe
With promising Ph3 data in hand, Incyte files for myelofibrosis drug OK
Fierce Biotech
Mon, 06/6/11 - 12:31 pm
Tags:
Incyte, myelofibrosis, ruxolitinib
Incyte Announces Ruxolitinib (INC424) Shows Significant Clinical Benefit for Myelofibrosis Patients in Two Phase III Studies at ASCO Annual Meeting
Yahoo/BusinessWire
Sun, 06/5/11 - 10:03 am
Tags:
Incyte, ruxolitinib, INC424, myelofibrosis
Novartis to showcase blockbuster cancer drug strategy at ASCO
Fierce Biotech
Wed, 06/1/11 - 06:44 pm
Tags:
Novartis, ASCO, JAK inhibitors, Incyte
Incyte and YM Biosciences in Race to Market Strongest JAK Inhibitor
Seeking Alpha
Thu, 04/21/11 - 11:46 am
Tags:
JAK inhibitors, YM BioSciences, Incyte, myelofibrosis
Top 15 Most Undervalued Biotech Stocks By Analyst Target Price
Seeking Alpha
Sat, 04/9/11 - 11:02 am
Tags:
Prolor, Lexicon Pharmaceuticals, Dendreon, Human Genome Sciences, Targacept, Sequenom, Cadence Pharmaceuticals, Savient, ONYX Pharmaceuticals, Amylin, Emergent BioSolutions, XenoPort, Spectrum Pharmaceuticals, Incyte, Amgen
Cancer Drug Stocks to Trade Ahead of ASCO
TheStreet.com
Tue, 03/22/11 - 10:03 am
Tags:
ASCO, Medivation, Exelixis, Dendreon, Bristol-Myers Squibb, Roche, Curis, Celgene, Sanofi, Ariad Pharmaceuticals, Merck, Incyte, Novartis, YM BioSciences, Pfizer, Aveo Pharmaceutical, ONYX Pharmaceuticals, Amgen, Synta, Vical, Oxigene, Cell Therapeutics, Oncothyreon
Novartis maps out a blockbuster future for INC424
Fierce Biotech
Wed, 03/16/11 - 09:21 am
Tags:
Novartis, INC424, Incyte, JAK inhibitors, ruxolitinib, myelofibrosis
Incyte cancer drug meets goal in Europe study
Yahoo/AP
Tue, 03/15/11 - 10:03 am
Tags:
Incyte, Europe, ruxolitinib, Novartis
5 Breakthrough Drugs for 2011
Barron's
Thu, 02/3/11 - 10:06 am
Tags:
Benlysta, Human Genome Sciences, GSK, ipilimumab, Bristol-Myers Squibb, Vertex Pharmaceuticals, JNJ, Telaprevir, Novartis, Incyte, INCB-18424, Xarelto, Bayer
Incyte: Myelofibrosis Drug Looks Promising
Seeking Alpha
Mon, 12/27/10 - 08:29 am
Tags:
Incyte, myelofibrosis
Incyte says cancer drug met goal in study
Yahoo/AP
Tue, 12/21/10 - 09:53 am
Tags:
Incyte, cancer
U.S. Pharma: Latest Analyst Actions
Seeking Alpha
Sun, 12/5/10 - 11:35 am
Tags:
Seattle Genetics, Incyte, Biodel, Cadence Pharmaceuticals, NeurogesX, Metabolix, Gilead Sciences, Pfizer
Neutral on Incyte
Yahoo/Zacks
Sat, 12/4/10 - 12:15 pm
Tags:
Incyte, investors
Biotech Calendar: Key Dates for December
TheStreet.com
Tue, 11/30/10 - 09:20 am
Tags:
Delcath, Arena Pharmaceuticals, RXi Pharmaceuticals, Cell Therapeutics, Amgen, Incyte, Celgene, Corcept Therapeutics, Affymax, Targacept, Exelixis, Orexigen, ONYX Pharmaceuticals, Seattle Genetics, MannKind, Alimera, AstraZeneca, Human Genome Sciences
Pfizer, Incyte and Eli Lilly drug developments could transform future of rheumatoid arthritis therapy
FT.com
Mon, 11/29/10 - 12:44 pm
Tags:
rheumatoid arthritis, Pfizer, Incyte, Eli Lilly, Rigel, JAK inhibitors, fostamatinib
Virgin Market for New Bone Marrow Cancer Drug
Minyanville
Sat, 11/27/10 - 12:32 pm
Tags:
Incyte, myelofibrosis, YM BioSciences, CYT387, ONYX Pharmaceuticals
Incyte Pharmaceuticals’ JAK: Just Another Kinase?
Seeking Alpha
Tue, 10/5/10 - 08:44 pm
Tags:
Incyte, Kinase, AstraZeneca, Eli Lilly, Sanofi, Janus kinase

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.